THE MODERN BIO ROADMAP / STAGE 03
CLINICAL CONTEXT FIRST
Advanced therapies
Turn interest into a clinician-ready decision—not a leap of faith.YOUR BRIEFPeptides, hormones, prescription therapies and facility-based treatments belong in a stricter process: define the indication, compare approved alternatives, verify the product and provider, establish monitoring and agree on stop rules.
Start the plan ↓ TIME HORIZONDecision first
LOADClinical complexity
FINISH LINEA documented indication, qualified care path, monitoring plan and informed yes—or an equally valuable no.
01 / START HERE
Make the first move today.
These are the highest-leverage entry points for this stage. Pick one now; use the complete plan when you are ready to build the sequence.02 / PLAN PREVIEW
See the sequence.
Track it privately.
Review every action, standard and signal here. Sign in when you are ready to save progress, record weekly changes and follow one clear next step.PUBLIC PLAN PREVIEWUnderstand the sequence here. Work the plan inside your private account.Your account saves completed actions, weekly check-ins, uploaded labs and practitioner guidance in one place.
Create account / sign in →01
GATE 1
Define the indication
Document the condition, symptom pattern, failed or unsuitable alternatives and the measurable treatment target.
ACTION STANDARDA clinician can explain why this therapy fits this problem now.Track: Indication + objective endpointBuild the diagnostic path ↗ 02
GATE 2
Verify regulatory and evidence status
Distinguish FDA approval, facility accreditation, compounding, off-label prescribing and research use. Read what human outcomes are—and are not—established.
ACTION STANDARDYou can state the exact status without marketing language.Track: Status + strongest relevant human evidenceCheck peptide status ↗ 03
GATE 3
Vet the provider and source
Confirm credentials, pharmacy or facility standards, product traceability, emergency procedures and who manages complications.
ACTION STANDARDThe care team answers safety questions before requesting payment.Track: Provider, source and escalation route verifiedSee a facility-first example ↗ 04
GATE 4
Establish monitoring
Agree on baseline symptoms, examination or labs, expected timeline, follow-up cadence and thresholds that trigger change or discontinuation.
05
GATE 5
Write the informed decision
List expected benefit, material uncertainty, common and serious risks, alternatives, total cost and fertility or long-term implications where relevant.
ACTION STANDARDYou understand the downside as clearly as the upside.Track: One-page benefit / risk / alternative briefOpen the evidence compass ↗ 06
GATE 6
Set the stop and exit plan
Decide what lack of response, side effect, lab change, sourcing problem or cost threshold ends the treatment—and how discontinuation is managed.
ACTION STANDARDThe exit plan exists before treatment starts.Track: Stop rules + responsible follow-up ownerReview safety boundaries ↗ READY TO BEGIN?Turn this roadmap into your saved transformation plan.
Start free while membership and practitioner services are being finalized. No fee is shown or charged today.
Open my private account →03 / THE SCORECARD
Measure only what can change the decision.
A useful dashboard is small enough to review every week and specific enough to expose whether the plan is working.01IndicationNamed condition or objective problem
The treatment cannot be judged without knowing what it is meant to change.
02StatusApproved / off-label / compounded / investigational
These pathways carry different evidence and oversight.
03MonitoringBaseline, cadence and stop thresholds
More powerful interventions require clearer surveillance.
04ProviderCredentials, source and complication plan
Product quality and clinical response are part of the intervention.
04 / READINESS GATE
Earn the next level.
Progress is not buying a more advanced intervention. It is moving forward with a stronger signal, a clearer reason and risk matched to oversight.ADVANCE WHEN- A qualified clinician has confirmed a plausible indication.
- Established alternatives and non-treatment have been compared honestly.
- The exact product, source, route, monitoring and stop plan are documented.
- Potential benefit is meaningful enough to justify uncertainty, burden and cost.
PAUSE OR GET HELP WHEN- The seller will not name the pharmacy, source, credentials or emergency process.
- The dose is copied from social media without diagnosis-specific context.
- Treatment begins before baseline evaluation or informed consent.
- Marketing promises broad anti-aging, healing or performance benefits from one therapy.
05 / GO DEEPER
Open the guide that moves the plan forward.
Every pathway connects to a complete Modern Bio guide with evidence context, practical actions, safety boundaries and the next decision.06 / SOURCE PACK
Ground rules from authoritative guidance.
EDUCATIONAL PLANNING TOOL This roadmap does not diagnose disease or replace care from a qualified professional who knows your history. Symptoms, pregnancy, medications, disability, age and existing conditions can change what is appropriate.